IgA Nephropathy: Current Treatment and New Insights

Area of Science:

• Nephrology
• Immunology
• Autoimmune Diseases

Background:

• IgA Nephropathy (IgAN) is the leading cause of primary glomerulonephritis globally.
• It is a heterogeneous autoimmune condition characterized by mesangial IgA deposition, leading to kidney damage.
• Disease progression is linked to proteinuria, hypertension, and reduced renal function, often resulting in end-stage kidney disease (ESKD).

Purpose of the Study:

• To review the current therapeutic strategies for IgA Nephropathy.
• To discuss novel investigational agents for IgAN treatment.
• To provide an overview of the evolving understanding of IgAN pathophysiology and treatment.

Main Methods:

• Literature review of current and emerging IgAN therapies.
• Synthesis of information on IgAN pathogenesis, clinical presentation, and risk factors.
• Analysis of the efficacy and safety of established and novel treatment approaches.

Main Results:

• Glucocorticoids have been a traditional treatment but offer limited long-term renal benefit and carry adverse effects.
• Recent advances in understanding IgAN pathophysiology have spurred the development of new therapeutic agents.
• Several novel investigational agents are showing promise in targeting specific disease pathways.

Conclusions:

• Current treatments for IgAN, including glucocorticoids, have limitations in efficacy and safety.
• A deeper understanding of IgAN pathogenesis is driving the development of targeted therapies.
• Novel therapeutic agents represent a promising future direction for managing IgAN and preventing disease progression.